Endostatin is under clinical development by Simcere Pharmaceutical Group and currently in Phase III for Malignant Pleural Effusion. According to GlobalData, Phase III drugs for Malignant Pleural Effusion have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Endostatin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Endostatin overview

Endostatin (Endostar/ Recombinant Human Endostatin) is a angiostatic protein prepared by using recombinant DNA technology. It is formulated as injectable solution for intravenous drip route of administration. Endostar in combination with NP chemotherapy regimen is indicated for the treatment of patients with stage III/IV non-small cell lung cancer. T Endostatin (Endostar/ Recombinant Human Endostatin) in combination with cisplatin is also under development for the treatment of malignant pleural effusion, malignant thoracoabdominal effusions, ascite, nasopharyngeal carcinoma and non-small cell lung cancer. It is administered through intravenous route. The drug candidate was under development for the treatment of peripheral T-cell lymphoma.

Simcere Pharmaceutical Group overview

Simcere Pharmaceutical Group (Simcere) is a pharmaceutical company discovers, develops, and markets branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas such as anti-tumor, anti-infection, central nervous, cardiovascular, skeletal muscle, and others. Its product portfolio includes recombinant human endostatin injection, palonosetron hydrochloride injection, nedaplatin for injection, fluorouracil implants and lyvamlodipine besylate tablets, among others. Simcere’s products are used for the treatment of oncology, infectious diseases, neurology, anti-inflammation and also cardiovascular diseases. The company conducts research and development focused on low end generics and APIs to innovative medicines. The company’s precision medicine sector, Simcere diagnostics had strategic partnership t with Agena bioscience focused on Agena’s Massarray System for companion diagnostics and pharmacogenetic testing in China. Simcere is headquartered in Nanjing, Jiangsu, China

For a complete picture of Endostatin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.